TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes

By A. Petitjean, M. Achatz, A. Børresen-Dale, Pierre Hainaut, Magali Olivier. Oncogene, 2007

914 citations recorded by the source corpus.

Subfields: Cancer Research, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/89a136157760d7c9b79d96ed71941fa9965bc934

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Molecular Biology

In Oncology

Citations in the corpus

Mutant p53 Disrupts Mammary Acinar Morphogenesis via the Mevalonate Pathway (2012, neutral): “The mutational status of p53 has been shown to predict poor outcomes in multiple types of human tumors, including breast cancer (Olivier et al., 2006; Petitjean et al., 2007).”
Mutant p53: one name, many proteins. (2012, background): “The great majority of these missense mutations are clustered within the central most conserved region of p53 that spans the DNA-binding domain, and among these are a small number (approximately six) of ‘‘hot spot’’ residues that occur with unusually high frequency (Fig. 1A,B; Harris and Hollstein 19”
Mutations in the p53 Tumor Suppressor Gene: Important Milestones at the Various Steps of Tumorigenesis. (2011, background): “An additional examination of the lung cancer p53 hotspot mutants revealed that they are all defective for transactivation ability with less than 20% of WT activity on all p53responsive elements.(47) It seems, therefore, that both a specific transversion associated with PAH adducts and loss of transa”
Mutant p53 in Cancer: New Functions and Therapeutic Opportunities (2014, background): “…considered to be equivalent, evidence is accumulating to indicate that different mutants show a distinct profile with respect to loss of wild-type p53 activity, the ability to inhibit wild-type p53, and the acquisition of gain of function (Table 1; Halevy et al., 1990; Petitjean et al., 2007).”
Uncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer (2020, background): “However, other genes, such as TP53, which is frequently mutated in human cancers [25], or EGFR, KRAS, and BRAF, which are mutations that often inform patient therapy [26], were not highly mutated in the high-risk subtype, suggesting that there may be other factors that can distinguish the different ”
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review (2021, background): “There have been many studies showing the prognostic role of p53 loss-of-function mutation in breast cancer [227,228].”
TP53 mutations in human cancers: origins, consequences, and clinical use. (2010, methodology): “Data from IARC TP53 Database (R13, November 2008)(Petitjean et al. 2007b).”
Mutant p53 drives invasion by promoting integrin recycling. (2009, background): “Similarly, in human cancers mutant p53 expression has been linked with a poorer prognosis (Petitjean et al., 2007).”
Mutant p53 gain-of-function in cancer. (2010, background): “Several recent reviews address in detail the various aspects of mutp53 GOF (Brosh and Rotter 2009; Donzelli et al. 2008; Lozano 2007; Olivier et al. 2009; Peart and Prives 2006; Petitjean et al. 2007; Song and Xu 2007; Strano et al. 2007; Weisz et al. 2007b).”
Blinded by the Light: The Growing Complexity of p53. (2009, result): “The concept that we should be trying to reactivate p53 in cancer cells is supported by experimental data and many human studies that show a correlation between mutations in p53 and poor disease prognosis (Petitjean et al., 2007).”